Bausch Health (BHC)
(Delayed Data from NYSE)
$7.12 USD
-0.01 (-0.14%)
Updated May 14, 2024 04:00 PM ET
After-Market: $7.20 +0.08 (1.12%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth F Momentum B VGM
Brokerage Reports
Bausch Health Cos Inc. [BHC]
Reports for Purchase
Showing records 121 - 140 ( 148 total )
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Progress on Multiple Fronts; 2019 Guidance Implies Gradual Growth; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Headwinds Abating; Debt Seems Manageable; Synergy Bid Intrigues; Upgrading to Buy and $58 Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
ALTRENO Lotion Pivotal Data Published; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
BRYHALI Lotion Receives Tentative FDA Approval; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R